ACRS (Aclaris Therapeutics) Total Assets: $198.72 Mil (As of Mar. 2026)


ACRS Aclaris Therapeutics Inc ACRS
38 GF Score
Price $5.02
GF Value $0.45
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Aclaris Therapeutics Total Assets?

Aclaris Therapeutics ACRS -0.30% 38 Total Assets is $198.72 Mil as of Mar. 2026. GuruFocus rates ACRS with a GF Score™ of 38/100 and a GF Value™ of $0.45 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Aclaris Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $198.72 Mil.

During the past 12 months, Aclaris Therapeutics's average Total Assets Growth Rate was 0.60% per year. During the past 3 years, the average Total Assets Growth Rate was 23.50% per year. During the past 5 years, the average Total Assets Growth Rate was 31.70% per year. During the past 10 years, the average Total Assets Growth Rate was 13.90% per year.

During the past 13 years, Aclaris Therapeutics's highest 3-Year average Total Assets Growth Rate was 253.10%. The lowest was -30.50%. And the median was 22.40%.

Total Assets is connected with ROA %. Aclaris Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -44.15%. Total Assets is also linked to Revenue through Asset Turnover. Aclaris Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.01.

Aclaris Therapeutics  (NAS:ACRS) Total Assets Explanation

Total Assets is connected with ROA %.

Aclaris Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-79.296/( (160.46+198.72)/ 2 )
=-79.296/179.59
=-44.15 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Aclaris Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=1.996/( (160.46+198.72)/ 2 )
=1.996/179.59
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Aclaris Therapeutics Total Assets Related Terms

Aclaris Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Aclaris Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aclaris Therapeutics Total Assets Chart

Aclaris Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 251.21 254.60 197.41 220.33 160.46

Aclaris Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 198.09 189.15 175.53 160.46 198.72
ACRS
38GF Score
Aclaris Therapeutics Inc ACRS
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aclaris Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Aclaris Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=103.082+57.378
=160.46

Aclaris Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=143.649+55.071
=198.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $198.72 Mil mean?
Aclaris Therapeutics (ACRS) has a Total Assets of $198.72 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Aclaris Therapeutics and its competitors.
Is Aclaris Therapeutics' Total Assets too high?
Aclaris Therapeutics' current Total Assets is $198.72 Mil. Overall, Aclaris Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aclaris Therapeutics' Total Assets compare to RLMD and GYRE?
Aclaris Therapeutics' Total Assets of $198.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Aclaris Therapeutics and its competitors. Aclaris Therapeutics's current Total Assets is $198.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclaris Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aclaris Therapeutics (ACRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $5.02 — trading 1015.6% above its estimated fair value. The current Total Assets is $198.72 Mil. Aclaris Therapeutics' overall GF Score™ is 38/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Aclaris Therapeutics (ACRS), the current Total Assets is $198.72 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aclaris Therapeutics (ACRS) Overvalued in 2026?

Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued. The current stock price of $5.02 is trading 1015.6% above its estimated GF Value™ of $0.45. GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.

Key valuation signals for ACRS:

  • Total Assets: $198.72 Mil
  • GF Value™: $0.45 vs. price of $5.02 (1015.6% above fair value)
  • GF Score™: 38/100 with 10 warning signs

No single metric tells the full story. See the ACRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aclaris Therapeutics Business Description

Other Exchanges 0H8T:UK8AT:Germany
Address 701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
38GF Score

Get the complete analysis for ACRS

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.02
Price
$0.45
GF Value